usdaed

that such growth demands a corresponding extraction. Someone will pay the price for these inflated valuations. And it won’t be the men in silk suits.

But here’s the thing about frenzies: they don’t last. Someone always crashes the party. And that’s where Viking Therapeutics comes in. A biotech, still wet behind the ears, but with a potential weapon in its arsenal: VK2735. Injectable and oral? Now you’re talking. A dual GIP/GLP-1 receptor agonist? Sounds like something out of a science fiction novel, but the results are… promising. Fourteen-point-seven percent weight loss in thirteen weeks? Without a plateau? That’s not incremental improvement, that’s a goddamn landslide. They’re playing with fire, and I, for one, am watching with a morbid fascination.

Should the usual suspects—those large, somewhat melancholic holders of American debt in, say, the European Union—decide to redistribute their affections, to subtly loosen their grip on these promises of future dollars, then Bitcoin, that digital phantom, might flutter into the conversation. Not as a solution, mind you—the world is rarely so accommodating—but as a potential beneficiary of disillusionment. Though, as with most things, a less flattering first response is, statistically speaking, the more probable outcome. Let us, therefore, dissect the likely choreography of a genuine Treasury unwind.

The initial lawsuit, filed in 2020, alleged a breach of financial securities laws, a bureaucratic accusation that, while ostensibly about compliance, felt more akin to a condemnation of existence. The very act of attempting to operate within the established system, it seemed, was a transgression. The settlement itself did not resolve the underlying structural inadequacies, but rather shifted the locus of anxiety from legal jeopardy to the more insidious realm of market forces – forces as opaque and unknowable as the intentions of the regulatory bodies themselves.

Joaquin Duato, the current steward of this vast enterprise, spoke of a “new era of accelerated growth” in the recent quarterly accounting. Such pronouncements, however, should be received not as declarations of triumph, but as carefully constructed narratives intended to mask the underlying complexities of a system perpetually grappling with its own contradictions. The question, therefore, is not whether growth is occurring, but rather, what is being grown, and for whose benefit?

the shoemaker prospers while the emperor parades in borrowed finery.

Nu Holdings, a Brazilian institution, presents itself as a disruptor, a liberator from the archaic bonds of traditional banking. But observe closely: it is merely a new form of creditor, extending lines of credit to a populace increasingly reliant on borrowed time. Its growth is undeniable – a proliferation of accounts, a swelling of revenue. Yet, this expansion occurs within a system predicated on indebtedness. The addition of 4.3 million customers in a single quarter is not a triumph of financial inclusion, but a testament to the ever-widening net of obligation. They report ‘flawless’ results, a phrase that should always raise a skeptical eyebrow. Such pronouncements rarely withstand the scrutiny of years, or the inevitable onset of systemic stress.

There is a veritable menagerie of these digital tokens, each promising salvation, each vying for attention like desperate petitioners before a capricious Tsar. Yet, amidst this clamor, one name persists, a name that, for better or worse, seems destined to endure. A fleeting opportunity, perhaps, though opportunities, like stray dogs, are rarely what they seem.

Brent Thill at Jefferies, a perfectly sensible chap, suggests Palantir might find itself trading at a more realistic $70 per share. A decline of 57%? Rather dramatic, of course, but not entirely unexpected given the current valuation. Harlan Sur at J.P. Morgan is equally unimpressed with Sandisk, proposing a target of $235 – a fall of 53%. One begins to wonder if these analysts have actually seen the numbers.